TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
DNA

Ginkgo Bioworks Holdings

Healthcare · Biotechnology

8.60$ -8.4% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

All figures as a percentage of total assets in the same period.

Tick rows to compare them in a chart (up to 4)

Balance Sheet DNA
Line item 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
73.4% 63.2% 83.2% 57.1% 60.2% 43.8% 42.1%
71.0% 56.4% 74.8% 51.8% 56.7% 40.8% 14.9%
71.0% 56.4% 74.8% 51.8% 56.7% 40.8% 37.7%
1.1% 3.2% 7.2% 3.3% 1.1% 1.6% 2.1%
0.0% 1.4% 0.2% 0.2% 0.0% – –
9.1% 18.0% 7.0% 28.2% 23.9% 43.4% 47.2%
0.3% 0.3% 1.0% 2.4% 3.0% 0.0% –
0.6% 0.5% 1.0% 4.4% 5.0% 5.3% 5.1%
28.0% 30.4% 24.3% 31.6% 34.1% 48.0% 54.6%
5.7% 10.8% 6.5% 6.8% 9.8% 7.8% 8.6%
0.1% 0.1% 0.0% 1.2% 1.0% 2.1% 2.0%
0.3% 2.1% 0.4% 0.4% 0.6% 1.0% 0.9%
70.7% 68.3% 72.7% 68.4% 65.9% 52.0% 45.4%
-48.9% -69.3% -111.0% -173.2% -317.7% -423.8% -549.3%
4.1% 4.7% 1.6% 1.7% 2.9% 3.8% 5.0%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?